Trial Profile
A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 May 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms SAVE
- 10 May 2022 Status changed from recruiting to completed.
- 01 Sep 2020 Planned End Date changed from 1 Jul 2020 to 1 Jul 2022.
- 01 Sep 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Jul 2021.